68Ga-PNT6555

INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the commercialization of PNT2002 & PNT2003. Upon consummation of the agreements, in exchange for the exclusive worldwide rights1, Lantheus will pay a total of $260 million in upfront payments between the two agreements to POINT, with the potential for additional milestone payments of approximately $1.8 billion between the two products based on U.S. Food and Drug Administration (FDA) approval and net sales and commercial milestones. Additionally, Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003. Additional terms of the agreements are summarized below and a website with more information about the collaboration is accessible at and the Company’s website. “We are very pleased to have reported the Lantheus strategic collaboration earlier this morning. The terms of the deal affirm for us the value of POINT’s platform and maximizes value for both shareholders and patients,” said Joe McCann, Ph.D., CEO of POINT Biopharma. “We founded POINT to accelerate the discovery, development, and global access to life-changing radiopharmaceuticals, and with this collaboration POINT is now better positioned than ever to execute on our mission. With our financial position further strengthened, we can continue to focus on our core competencies and dedicate resources to our pipeline. Specifically, we believe that PNT2004 is an incredibly exciting, high value opportunity. PNT2004 is our pan-cancer FAP-α program, which is currently in Phase 1. We will also continue to invest in PNT2001, our actinium-225 next-generation PSMA program, which is expected to begin Phase 1 in 2023, and other next-generation radioligand opportunities.” Recent Developments and Upcoming Milestones Pipeline Updates PNT2002: 177Lu-based PSMA targeted radiopharmaceutical In September 2022, the Company published a poster at ESMO Congress 2022 containing efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the Company’s phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The poster was titled “Efficacy and Safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH” (e-Poster #1400P). Key findings include a median rPFS time of 11.5 months, along with a well-tolerated safety pro no treatment-related deaths and few treatment-related adverse events of grade 3 or higher. The SPLASH trial is currently enrolling patients across 55 sites in North America, Europe, and United Kingdom, and recruitment is expected to be completed by the end of the calendar year. The Company continues to expect to report top line data from SPLASH in mid-2023. PNT2004: fibroblast activation protein-alpha (FAP-alpha) targeted radiopharmaceutical The phase 1 FRONTIER trial (NCT05432193) for the Company’s pan-cancer fibroblast activation protein-α (FAP-α) targeted program, PNT2004, commenced in July 2022. FRONTIER is evaluating PNT6555 (the lead candidate of PNT2004) in approximately 30 patients in five FAP-avid cancer indications: colorectal, pancreatic, esophageal, melanoma, and soft tissue sarcomas. A gallium-68 (68Ga)-based PNT6555 molecular imaging agent is being used to select patients for the study, those selected then receive a no-carrier-added (n.c.a.) lutetium-177 (177Lu)-based PNT6555 therapeutic agent. The primary objective of the study is to determine the recommended phase 2 dose (RP2D), as guided by a modified toxicity probability interval-2 design. Phase 1 data from FRONTIER is expected in H1 2024. PNT2001: 225Ac-labelled next-generation PSMA-targeted radiopharmaceutical In October 2022, POINT published promising new pre-clinical data from the Company’s next-generation radioligand therapy (RLT) program for prostate cancer, PNT2001. The new PNT2001 data were shared in E-poster #039, “Development and characterization of a next-generation 225Ac-PMSA radioligand,” at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona, Spain. The Company is targeting an IND/CTA submission for PNT2001 in H1 2023, with the first patient expected for a phase 1 clinical trial by EOY 2023. Corporate Updates: In September 2022, the Company closed a previously announced underwritten public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share. Subsequent to closing, the underwriter exercised its option to purchase an additional 1,589,779 shares. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $140 million. Upcoming Investor Conferences Management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference Format: Company Presentation (in person) and 1x1 Meetings Date: Tuesday, November 15, 2022 Time: 5:00pm GMT Piper Sandler 34th Annual Healthcare Conference Format: Fireside Chat (in person) and 1x1 Meetings Date: Tuesday, November 29, 2022 Time: 8:30am EST 5th Annual Evercore ISI HealthCONx Conference Format: 1x1 Meetings (virtual) Date: Wednesday, November 30, 2022 Three Months and Nine Months Ended 2022 Financial Results Cash, Cash Equivalents and Investments: As of September 30, 2022, POINT had approximately $291.5 million in cash, cash equivalents and investments, which is anticipated to fund operations into the fourth quarter of 2024. Net Loss: Net loss was $24.0 million, or $0.26 net loss per share, for the three months ended September 30, 2022, as compared to a net loss of $17.1 million, or $0.19 net loss per share, for the same period in 2021. Net loss was $65.0 million, or $0.71 net loss per share, for the nine months ended September 30, 2022, as compared to a net loss of $31.7 million, or $0.46 net loss per share, for the same period in 2021. Research and Development Expenses: Research and development expenses were $20.8 million for the three months ended September 30, 2022, as compared to $13.0 million for the same period in 2021. Research and development expenses were $54.1 million for the nine months ended September 30, 2022, as compared to $24.0 million for the same period in 2021. General and Administrative Expenses: General and administrative expenses were $3.8 million for the three months ended September 30, 2022, as compared to $4.0 million for the same period in 2021. General and administrative expenses were $11.7 million for the nine months ended September 30, 2022, as compared to $7.4 million for the same period in 2021. 1 Excluding the following territories: China (inclusive of Taiwan, Hong Kong and Macau), Japan, South Korea, Indonesia and Singapore, which are retained by POINT. About the SPLASH Trial The phase 3 SPLASH trial is a multi-center, randomized, open label assessment of PNT2002 in participants with PSMA-expressing mCRPC who have progressed on androgen receptor pathway inhibitor (ARPI) therapy and refuse, or are not eligible for, chemotherapy. The randomization phase of the study is expected to enroll approximately 400 participants across North America, Europe, and the United Kingdom. Participants will be randomized 2:1 with participants in arm A receiving PNT2002 and participants in arm B receiving either abiraterone or enzalutamide. Participants in arm B who experience centrally assessed radiographic progression and meet protocol eligibility will have the option to crossover and receive PNT2002. Patients will be subject to follow-up for up to 5 years from their first PNT2002 dose. The primary endpoint of the study is radiographic progression-free survival. Key secondary endpoints include overall response rate, overall survival, and pharmacokinetics. About the FRONTIER Trial The FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability, and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients with Select Solid Tumors (FRONTIER) trial is an open-label, phase 1 trial to evaluate safety, tolerability, and dosimetry of 177Lu-PNT6555 and 68Ga-PNT6555, the lead assets of the PNT2004 program. The phase 1 clinical trial commenced in summer 2022 in Canada and uses a 68Ga-based PNT6555 molecular imaging agent to select patients to receive a no-carrier-added (n.c.a.) 177Lu-based PNT6555 therapeutic agent. The phase 1 clinical protocol will evaluate PNT6555 in approximately 30 patients in five FAP-avid cancer indications: colorectal, pancreatic, esophageal, melanoma, and soft tissue sarcoma. About POINT Biopharma Global Inc. POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (225Ac) and lutetium-177 (177Lu). POINT’s active clinical trials include FRONTIER, the phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. More information about the SPLASH trial can be found at . Learn more about POINT Biopharma Global Inc. at . Forward Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, our ability to grow and manage our growth profitably and retain our key employees, the impact of COVID-19 on our business, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, our ability to obtain funding for our operations, our ability to maintain the listing of our common stock on NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described in our Annual Report on Form 10-K filed with the SEC on March 25, 2022. Many of these factors are outside of POINT’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Investor Relations Contact: Daniel Pearlstein Associate Director, Corporate Strategy investors@pointbiopharma.com Unaudited Interim Condensed Consolidated Statements of Operations (In U.S. dollars) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses: Research and development 20,797,406 13,004,649 54,112,136 23,974,809 General and administrative 3,839,626 4,026,666 11,727,969 7,440,910 Total operating expenses 24,637,032 17,031,315 65,840,105 31,415,719 Loss from operations (24,637,032 ) (17,031,315 ) (65,840,105 ) (31,415,719 ) Other income (expenses): Finance income (costs) 1,048,254 (6,178 ) 1,605,927 (11,840 ) Foreign currency (loss) gain (243,791 ) 1,905 (287,691 ) (32,901 ) Total other income (expenses) 804,463 (4,273 ) 1,318,236 (44,741 ) Loss before provision for income taxes (23,832,569 ) (17,035,588 ) (64,521,869 ) (31,460,460 ) Provision for income taxes (180,500 ) (81,044 ) (452,021 ) (245,251 ) Net loss $ (24,013,069 ) $ (17,116,632 ) $ (64,973,890 ) $ (31,705,711 ) Net loss per basic and diluted common share: Basic and diluted net loss per common share $ (0.26 ) $ (0.19 ) $ (0.71 ) $ (0.46 ) Basic and diluted weighted average common shares outstanding 92,401,484 90,121,794 90,891,031 68,317,492 Interim Condensed Consolidated Balance Sheets (In U.S. dollars) September 30, 2022 (Unaudited) December 31, 2021 $ $ ASSETS Current assets Cash and cash equivalents 125,783,126 238,815,991 Short-term investments 165,735,511 — Prepaid expenses and other current assets 4,711,979 5,030,565 Total current assets 296,230,616 243,846,556 Non-current assets Property, plant and equipment, net 29,457,230 19,412,086 Total non-current assets 29,457,230 19,412,086 Total assets 325,687,846 263,258,642 LIABILITIES & STOCKHOLDERS' EQUITY Current liabilities Accounts payable 3,198,646 1,738,470 Accrued liabilities 13,047,645 5,990,516 Income taxes payable 361,723 250,978 Total current liabilities 16,608,014 7,979,964 Deferred tax liability — 65,592 Total liabilities 16,608,014 8,045,556 Commitments and contingencies Stockholders’ equity Common Stock, par value $0.0001 per share, 430,000,000 authorized, 104,054,962 and 90,121,794 issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 10,405 9,012 Additional paid-in capital 433,936,723 314,488,782 Accumulated deficit (124,258,598 ) (59,284,708 ) Accumulated other comprehensive loss (608,698 ) — Total stockholders’ equity 309,079,832 255,213,086 Total liabilities and stockholders’ equity 325,687,846 263,258,642

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters Phase 1 clinical trial INDIANAPOLIS, Aug. 12, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2022 and provided an update on business highlights. “We continue to execute across our pipeline and platform,” said Dr. Joe McCann, CEO of POINT Biopharma. “The Phase 3 SPLASH trial in pre-chemotherapy mCRPC began European randomization in the second quarter, and I look forward to the release of further data from the 27-patient lead-in of the SPLASH trial this fall.” "One of the achievements from this past quarter I am most proud of is the commencement of the FRONTIER trial - the Phase 1 trial for PNT2004, our pan-cancer fibroblast activation protein targeted program,” Dr. McCann continued. “This program is a true cross-functional collaboration highlighting POINT's strengths in chemistry, radiochemistry, biology, clinical development and regulatory to enable the acceleration of radioligand discovery, progressing from in-license of a non-radiopharmaceutical molecule to a Phase 1 trial for both an imaging agent and a therapeutic agent in just 2 years. 68Ga-PNT6555 and 177Lu-PNT6555, the leads of the PNT2004 program, have now advanced into the clinic, a significant step forward in the development of a pan-cancer theranostic.” Recent Developments and Upcoming Milestones Pipeline Updates PNT2002: 177Lu-based PSMA targeted radiopharmaceutical In April 2022, the Company dosed its first European Union patient in the SPLASH trial. The SPLASH trial is currently enrolling patients across 53 sites in North America, Europe, and UK, and site activations remain ongoing to expedite accrual. The Company continues to expect to report top line data from SPLASH mid-2023. PNT2004: fibroblast activation protein-alpha (FAP-alpha) targeted radiopharmaceutical The Company filed a clinical trial application (CTA) with Health Canada at the end of the first quarter of 2022 for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) targeted program, and a No Objection Letter was received from Health Canada in May 2022. The first patient was dosed in FRONTIER in July 2022. The Company also presented posters on PNT6555 at two recent academic conferences including the American Association for Cancer Research (AACR) 2022 Annual Meeting in April 2022, and the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting in June 2022. Both posters are accessible at https://www.pointbiopharma.com/investors#investor-presentations Management Updates: In June 2022, the Company appointed Chris Horvath as Executive Vice President, Commercial. Mr. Horvath brings almost twenty years of experience in the pharmaceutical industry, having led or worked on the launch of a number of key oncology products, including Pluvicto (lutetium 177Lu vipivotide tetraxetan), Locametz (gallium 68Ga gozetotide), Nubeqa (darolutamide), and Zytiga (abiraterone acetate). In his new role at POINT, Mr. Horvath will lead the commercial strategy for POINT’s pipeline. Mr. Horvath began his career as a scientist, working at both DuPont and Novartis Institutes for BioMedical Research. He then transitioned to commercial roles of increasing responsibility at Janssen, Dendreon, Merck, Bayer, and most recently Advanced Accelerator Applications (Novartis). Mr. Horvath holds a BSc in Chemistry & Biology from Wilfrid Laurier University, a MSc in Analytical Science from the University of Guelph, and an MBA from Rutgers Business School. Three Months and Six Months Ended 2022 Financial Results Cash, Cash Equivalents and Investments: As of June 30, 2022, POINT had approximately $204.3 million in cash, cash equivalents and investments, which is anticipated to fund operations into the first quarter of 2024. Net Loss: Net loss was $24.6 million, or $0.27 net loss per share, for the three months ended June 30, 2022, as compared to a net loss of $8.8 million, or $0.15 net loss per share, for the same period in 2021. Net loss was $41.0 million, or $0.45 net loss per share, for the six months ended June 30, 2022, as compared to a net loss of $14.6 million, or $0.26 net loss per share, for the same period in 2021. Research and Development Expenses: Research and development expenses were $20.8 million for the three months ended June 30, 2022, as compared to $6.7 million for the same period in 2021. Research and development expenses were $33.3 million for the six months ended June 30, 2022, as compared to $11.0 million for the same period in 2021. General and Administrative Expenses: General and administrative expenses were $4.1 million for the three months ended June 30, 2022, as compared to $1.9 million for the same period in 2021. General and administrative expenses were $7.9 million for the six months ended June 30, 2022, as compared to $3.4 million for the same period in 2021. About POINT Biopharma POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is transforming precision medicine by combining a portfolio of best-in-class radio-pharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like 225Ac and 177Lu. Learn more about POINT Biopharma Global Inc. at https://www.pointbiopharma.com/. Information about POINT Biopharma Global Inc.’s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/. About the FRONTIER Trial The FRONTIER trial is an open-label, Phase 1 trial to evaluate safety, tolerability and dosimetry of 177Lu-PNT6555 and 68Ga-PNT6555, the lead assets of the PNT2004 program. The Phase 1 clinical trial commenced in summer 2022 in Canada and uses a gallium-68 (68Ga)-based PNT6555 molecular imaging agent to select patients to receive a no-carrier-added (n.c.a.) lutetium-177 (177Lu)-based PNT6555 therapeutic agent. The Phase 1 clinical protocol will evaluate PNT6555 in ~30 patients in five FAP-avid cancer indications: colorectal, pancreatic, esophageal, melanoma, and soft tissue sarcoma. About the SPLASH Trial The Phase 3 SPLASH trial is a multi-center, randomized, open label assessment of PNT2002 in patients with PSMA-expressing mCRPC who have progressed on Androgen receptor-axis-targeted therapies (ARAT) therapy and refuse, or are not eligible for, chemotherapy. The randomization phase of the study is expected to enroll approximately 400 patients across North America, Europe and the United Kingdom. Patients will be randomized 2:1 with patients in arm A receiving PNT2002 and patients in arm B receiving either Abiraterone or Enzalutamide. Patients in arm B who experience centrally assessed radiographic progression and meet protocol eligibility will have the option to crossover and receive PNT2002. Patients will be subject to follow-up for up to 5 years from first PNT2002 dose. The primary endpoint of the study is radiographic progression-free survival (rPFS). Key secondary endpoints include overall response rate (ORR), overall survival (OS), and pharmacokinetics (PK). POINT anticipates meeting with regulatory agencies in North America, United Kingdom and Europe to gain alignment on requirements for planned submissions after data readout from the SPLASH trial. Additional information on the Phase 3 SPLASH trial can be found at https://www.splashtrial.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, our ability to grow and manage our growth profitably and retain our key employees, the impact of COVID-19 on our business, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, our ability to obtain funding for our operations, our ability to maintain the listing of our common stock on NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described in our Annual Report on Form 10-K filed with the SEC on March 25, 2022. Many of these factors are outside of POINT’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Investor Relations Contact:Daniel PearlsteinAssociate Director, Corporate Strategyinvestors@pointbiopharma.com Unaudited Interim Condensed Consolidated Statements of Operations (In U.S. dollars) For the Three Months EndedJune 30, For the Six Months EndedJune 30,(In U.S. dollars) 2022 2021 2022 2021 Operating expenses: Research and development 20,813,882 6,700,862 33,314,730 10,970,160 General and administrative 4,080,401 1,949,552 7,888,343 3,414,244 Total operating expenses 24,894,283 8,650,414 41,203,073 14,384,404 Loss from operations (24,894,283) (8,650,414) (41,203,073) (14,384,404)Other income (expenses): Finance income (costs) 509,700 (2,863) 557,673 (5,662)Foreign currency loss (12,259) (27,599) (43,900) (34,806)Total other income (expenses) 497,441 (30,462) 513,773 (40,468)Loss before provision for income taxes (24,396,842) (8,680,876) (40,689,300) (14,424,872)Provision for income taxes (183,405) (123,782) (271,521) (164,207)Net loss $ (24,580,247) $ (8,804,658) $ (40,960,821) $ (14,589,079) Net loss per basic and diluted common share: Basic and diluted net loss per common share $ (0.27) $ (0.15) $ (0.45) $ (0.26)Basic and diluted weighted average common shares outstanding 90,124,295 57,582,025 90,123,288 57,116,747 Interim Condensed Consolidated Balance Sheets (In U.S. dollars) June 30, 2022(Unaudited) December 31, 2021 $ $ASSETS Current assets Cash and cash equivalents78,108,242 238,815,991 Short-term investments121,324,415 — Prepaid expenses and other current assets5,472,394 5,030,565 Total current assets204,905,051 243,846,556 Non-current assets Long-term investments4,898,296 — Property, plant and equipment, net24,441,275 19,412,086 Total non-current assets29,339,571 19,412,086 Total assets 234,244,622 263,258,642 LIABILITIES & STOCKHOLDERS' EQUITY Current liabilities Accounts payable8,066,604 1,738,470 Accrued liabilities10,220,720 5,990,516 Income taxes payable509,403 250,978 Total current liabilities18,796,727 7,979,964 Deferred tax liability65,592 65,592 Total liabilities 18,862,319 8,045,556 Commitments and contingencies Stockholders’ equity Common Stock, par value $0.0001 per share, 430,000,000 authorized, 90,124,962 and 90,121,794 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively9,012 9,012 Additional paid-in capital315,961,198 314,488,782 Accumulated deficit(100,245,529) (59,284,708)Accumulated other comprehensive loss(342,378) — Total stockholders’ equity215,382,303 255,213,086 Total liabilities and stockholders’ equity234,244,622 263,258,642